NCT05091567 2026-03-10IMforteHoffmann-La RochePhase 3 Active not recruiting660 enrolled 23 charts 1 FDA
NCT01831089 2020-04-10Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid TumorsPharmaMarPhase 1 Completed69 enrolled 17 charts
NCT01951157 2019-09-24A Clinical Study in Three-arm of Lurbinectedin (PM01183) Alone or in Combination With Gemcitabine and a Control Arm With Docetaxel as Second Line Treatment in Non-Small Cell Lung Cancer (NSCLC) PatientsPharmaMarPhase 2 Completed69 enrolled 28 charts